Abstract
Non-pharmaceutical interventions (NPIs) were implemented to cope with the coronavirus disease 2019 (COVID-19) pandemic in South Korea. These interventions could also have affected other infectious diseases, but there have been no comprehensive studies regarding their impacts. This study examined trends in notifiable infectious diseases in both humans and animals during the COVID-19 pandemic. Autoregressive integrated moving average (ARIMA) models were developed for each disease using data from 2016 to 2019, and the incidences for 2020 to 2021 were predicted. Subsequently, the predicted numbers of cases were compared with actual observations. Our findings indicated a substantial reduction in human respiratory infectious diseases during implementation of NPIs. However, human gastrointestinal infectious diseases and livestock diseases did not show a significant decrease. The results revealed that the preventive effect sizes of NPIs varied among diseases and indicated the potential for side effects, suggesting that complementary interventions are needed to minimize these negative effects.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation, funded by the Korean government (No. 2021M3E5E3081366).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
